Status:
UNKNOWN
Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment
Lead Sponsor:
Auxilio Mutuo Cancer Center
Conditions:
Covid19
Cancer
Eligibility:
All Genders
21+ years
Brief Summary
This is a Phase II study designed to investigate if the Covid 19 vaccines are capable of eliciting production of antibodies against S protein of Sar-S-Cov-2 virus among patients with medical history o...
Eligibility Criteria
Inclusion
- All patients either diagnosed with cancer or with HIV positivity or treated with an antineoplastic regimen including anti CD-20 after Covid-19 vaccine will be registered on the study regardless of their type of cancer or type of antineoplastic regimen.
- Patients 21 years or older diagnosed with cancer treated with antineoplastic regimen or anti CD-20, or with HIV infection vaccinated with 2 doses of anti Covid-19 vaccine.
- Eligible patients will be registered on study after a Covid -19 vaccine has been scheduled.
- In order to be screened for Covid 19 antibodies, they must be tested at least two weeks after the second dose of Covid-19 vaccination.
Exclusion
- Anyone who has not been treated with anti-CD20 antibodies or with chemotherapy who doesn't have HIV infection or who has not received chemotherapy for cancer.
Key Trial Info
Start Date :
February 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04779996
Start Date
February 16 2021
End Date
February 28 2022
Last Update
March 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auxilio Mutuo Cancer Center
San Juan, Puerto Rico, 00918